Marco Foppoli

Biography

Dr. Marco Foppoli currently holds the position of Head of the Internal Medicine Unit at Policlinico San Marco di Zingonia.

He is also responsible for the Functional Unit of Onco-Hematology, which is part of the Hematology and Bone Marrow Transplant Division at IRCCS Ospedale San Raffaele, directed by Professor Fabio Ciceri. He also serves as the head of clinical activities in the inpatient setting within the Lymphoma Unit of the same institution.

After graduating from the Milan State University in Medicine and Surgery in 1985, he received a specialization in 1988 in clinical and laboratory hematology at the same institute.

After 15 years of working as a therapist at the Department of Internal Medicine under the guidance of Professor Claudio Rugarli, Dr. Foppoli has been engaged in diagnostics, therapy and follow-up (outpatient and inpatient) for about 20 years, with special emphasis on lymphomas, chronic lymphocytic leukemia and multiple myeloma in both traditional and extended treatment (high-dose chemoimmunotherapy, autograft, allograft).

In addition, he is engaged in the diagnosis, clinical management and follow-up of platelet disorders in the periphery and in the center.

Marco Foppoli also manages the clinical coordination of complex patients, with a global internist specialist perspective, throughout their interdisciplinary path and in his role as Head of the Internal Medicine Unit at Policlinico San Marco.

From a research point of view, he manages numerous protocols of clinical, diagnostic studies, as well as research in terms of treatment, including with innovative molecules in phase 1. He is also involved in therapeutic protocols with CAR-T.

He is the author and co-author of numerous articles published in scientific journals. He constantly participates in national and international congresses, courses and conferences.

Read moreRead less

Education

University of Milan
Bachelor's Degree in Medicine and Surgery - 1985

University of Milan
Specialization in clinical and laboratory hematology - 1988

Do you need an appointment?

Contact us and we will take care of you.

Publications

Latest publications

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma.
Blood. 2019 Jul 18;134(3):252-262. doi:10.1182/blood.2019000633. Epub 2019 May 22
Ferreri AJM, Calimeri T, Conte GM, Cattaneo D, Fallanca F, Ponzoni M, Scarano E, Curnis F, Nonis A, Lopedote P, Citterio G, Politi LS, Foppoli M, Girlanda S, Sassone M, Perrone S, Cecchetti C, Ciceri F, Bordignon C, Corti A, Anzalone N.
Read more
Interleukin-1 Receptor Blockade Rescues Myocarditis- Associated End-Stage Heart Failure.
Front Immunol. 2017 Feb 9;8:131. doi:10.3389/fimmu.2017.00131. eCollection 2017
Cavalli G, Foppoli M, Cabrini L, Dinarello CA, Tresoldi M, Dagna L.
Read more
Primary Cardiac Lymphoma in an Immunocompetent 71- Year-Old Man.
Tex Heart Inst J. 2015 Dec 1;42(6):561-4. doi: 10.14503/THIJ-14-4269. eCollection 2015 Dec
Montanaro C, Loiacono F, Fragasso G, De Cobelli F, Foppoli M, Margonato A.
Read more
High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem- Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.
J Clin Oncol. 2015 Nov 20;33(33):3903-10. doi: 10.1200/JCO.2015.61.1236. Epub 2015 Aug 17
Ferreri AJ, Donadoni G, Cabras MG, Patti C, Mian M, Zambello R, Tarella C, Di Nicola M, D'Arco AM, Doa G, Bruno-Ventre M, Assanelli A, Foppoli M, Citterio G, Fanni A, Mulè A, Caligaris-Cappio F, Ciceri F.
Read more
Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Br J Haematol. 2015 Mar;168(5):654-62. doi: 10.1111/bjh.13194. Epub 2014 Oct 14.
Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, Vignati A, Scarfò L, Sassone M, Govi S, Caligaris-Cappio F.
Read more
Gamma-delta t-cell lymphomas
Eur J Haematol. 2015 Mar;94(3):206-18. doi:10.1111/ejh.12439. Epub 2014 Oct 1
Foppoli M, Ferreri AJ.
Read more
The primary mediastinal lymphoma: state of the art and therapeutical perspectives.
Recenti Prog Med. 2013 May;104(5):203-8. doi:10.1701/1291.14277. Review
Foppoli M, Citterio G, Donadoni G, Govi S, Ferreri AJ.
Read more
Cardiac involvement by non-Hodgkin's lymphoma in an HIV-positive patient with hypertrophic obstructive cardiomyopathy.
Recenti Prog Med. 2012 Dec;103(12):575-7. doi:10.1701/1206.13359
Demarchi B, Foppoli M, Contri R, Margonato A.
Read more
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexatebased chemotherapy
Hematol Oncol. 2013 Sep;31(3):143-50. doi:10.1002/hon.2037. Epub 2012 Nov 14
Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Sorarù M, Vianello F, Baldini L, Proserpio I, Foppoli M, Assanelli A, Reni M, Caligaris-Cappio F, Ferreri AJ.
Read more
Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma.
Br J Haematol. 2012 Oct;159(2):252-5. doi:10.1111/bjh.12020. Epub 2012 Aug 25.
Ferreri AJ, Bruno Ventre M, Donadoni G, Cattaneo C, Fumagalli L, Foppoli M, Mappa S, Govi S, Di Nicola M, Rossi G, Tirelli U, Caligaris-Cappio F, Spina M, Re A.
Read more
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination.
Oncologist. 2011;16(3):336-41. doi: 10.1634/theoncologist.2010-0361. Epub 2011 Feb 23
Ferreri AJ, Licata G, Foppoli M, Corazzelli G, Zucca E, Stelitano C, Zaja F, Fava S, Paolini R, Franzin A, Politi LS, Ponzoni M, Reni M.
Read more
Treatment approaches for primary CNS lymphomas.
Expert Opin Pharmacother. 2010 Jun;11(8):1263-76. doi: 10.1517/14656561003767456. Review
Carrabba MG, Reni M, Foppoli M, Chiara A, Franzin A, Politi LS, Villa E, Ciceri F, Ferreri AJ.
Read more
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Lancet. 2009 Oct 31;374(9700):1512-20. doi: 10.1016/S0140-6736(09)61416-1. Epub 2009 Sep 18
Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F;International Extranodal Lymphom
Read more
Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate.
Cancer Lett. 2007 Dec 18;258(2):165-70. Epub 2007 Nov 13. Review
Reni M, Mazza E, Foppoli M, Ferreri AJ.
Read more
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
Neurology. 2006 May 9;66(9):1435-8
Ferreri AJ, Dell'Oro S, Foppoli M, Bernardi M, Brandes AA, Tosoni A, Montanari M, Balzarotti M, Spina M, Ilariucci F, Zaja F, Stelitano C, Bobbio F, Corazzelli G, Baldini L, Ponzoni M, Picozzi P, Caligaris Cappio F, Reni M.
Read more

Do you need an appointment?

Contact us and we will take care of you.